Effect of bisphosphonates on bone giant cell tumor recurrence: a meta-analysis

• Published in: Beni-Suef University Journal of Basic and Applied Sciences Vol. 11; no. 1; pp. 1 - 8
• Main Authors: Mohsen, Marwa, Osama, Hasnaa, Nicola, Mina, Saeed, Haitham, Abdelrahim, Mohamed E. A.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.12.2022; Springer; SpringerOpen
• Subjects: Adjuvant treatment; Analysis; Bisphosphonates; Cancer; Diseases; Giant cell tumor of bone; Intralesional curettage; Medicine; Medicine & Public Health; Phosphonates; Recurrence; Relapse; Tumors; Wide resection; Giant cell tumor of bone; Intralesional curettage; Recurrence; Bisphosphonates; Wide resection
• DOI: 10.1186/s43088-022-00292-2
• ISSN: 2314-8543; 2314-8535

Background We examined the impact of bisphosphonates as adjuvant therapy on the recurrence of giant cell bone tumors and the impact of various tumor stages and surgical techniques on this effect. Following a thorough examination of the literature up to January 2022, 10 studies including 601 adults with giant cell tumors of the bone were reported; 295 of these subjects received bisphosphonates as adjuvant therapy following surgery, and 306 served as the control group. To examine the possibility of lowering the recurrence of giant cell bone tumors, a comparison between bisphosphonates and a control group was made. In order to evaluate the impact of bisphosphonates as adjuvant therapy on the recurrence of the giant cell bone tumor, odds ratios (OR) with 95% confidence intervals (CIs) were determined. Additionally, the dichotomous technique with a random or fixed-effect model was used to examine the effects of various tumor stages and pertinent surgical procedures. Results Patients with giant cell tumors of the bone who received bisphosphonates as adjuvant therapy had significantly lower postoperative recurrence rates outcomes in all subjects with giant cell tumor of bone (OR 0.19; 95% CI 0.12–0.31, p  = 0.001), patients with stage I–II giant cell tumors of the bone (OR 0.29; 95% CI 0.11–0.76, p  = 0.01), patients with stage III giant cell tumors of the bone (OR 0.17; 95% CI 0.07–0.42, p  < 0.001); and post-intralesional curettage (OR 0.18; 95% CI 0.06–0.49, p  < 0.001) compared to control. Bisphosphonates were used in participants with giant cell tumors of the bone after broad excision, but there was no discernible difference between the two groups in terms of postoperative recurrence outcomes (OR 0.66; 95% CI 0.11–3.91, p  = 0.65). Conclusions In patients with giant cell tumors of the bone after intralesional curettage, the use of bisphosphonates as adjuvant therapy may lower the incidence of postoperative recurrence outcomes, but no appreciable difference was identified after extensive resection. According to the observed relationship, using bisphosphonates is advised to lower the likelihood of postoperative recurrence that can happen in patients with giant cell tumors of the bone.